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Mesenchymal stem cells (MSCs) have a great potential for treating equine musculoskeletal injuries. Although
their mechanisms of action are not completely known, their immunomodulatory properties appear to be key in
their functions. The expression of immunoregulatory molecules by MSCs is regulated by proinflammatory cyto-
kines; so inflammatory priming of MSCs might improve their therapeutic potential. However, inflammatory
environment could also increase MSC immunogenicity and decrease MSC viability and differentiation capacity.
The aim of this study was to assess the effect of cytokine priming on equine bone marrow-derived MSC (eBM-
MSC) immunoregulation, immunogenicity, viability, and differentiation potential, to enhance MSC immunoreg-
ulatory properties, without impairing their immune-evasive status, viability, and plasticity. Equine BM-MSCs
(n= 4) were exposed to 5 ng/mL of TNFa and IFNg for 12 h (CK5-priming). Subsequently, expression of genes
coding for immunomodulatory, immunogenic, and apoptosis-related molecules was analyzed by real-time quan-
titative polymerase chain reaction. Chromatin integrity and proliferation assays were assessed to evaluate cell
viability. Trilineage differentiationwas evaluated by specific staining and gene expression. Cells were reseeded in a
basal medium for additional 7 days post-CK5 to elucidate if priming-induced changes were maintained along the
time. CK5-priming led to an upregulation of immunoregulatory genes IDO, iNOS, IL-6, COX-2, and VCAM-1.
MHC-II and CD40 were also upregulated, but no change in other costimulatory molecules was observed. These
changes were not maintained 7 days after CK5-priming. Viability and differentiation potential were maintained
after CK5-priming. These findings suggest that CK5-priming of eBM-MSCs could improve their in vivo effec-
tiveness without affecting other eBM-MSC properties.
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Introduction
Mesenchymal stem cells (MSCs) are a promising toolfor treating musculoskeletal injuries in horses, but their
mechanisms of action are not fully understood. Despite the
low ability ofMSCs for engrafting in tissues such as cartilage,
these cells elicit therapeutic benefits. This effect has been
attributed to the immunomodulatory and anti-inflammatory
properties ofMSCs, suggesting that these abilities are implied
in their therapeutic role [1,2]. The MSC immunoregulatory
mechanism is a multifactorial process involving both direct
cell-to-cell contact and contact-independent paracrine sig-
naling. The expression of several molecules implied in MSC
immunomodulation is regulated by proinflammatory mole-
cules, such as interferon g (IFNg) and tumor necrosis factor a
(TNFa) [3]. Since MSC priming through exposure to an in-
flammatory environment may be needed for developing
their full regulatory function, stimulating MSCs with proin-
flammatory cytokines in vitro, before their in vivo adminis-
tration, is an interesting approach for improving their
therapeutic potential [4]. Nevertheless, inflammatory expo-
sure could also increase MSC immunogenicity [5], impair
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MSC differentiation capacity [6–8], and diminish MSC via-
bility [9]. Therefore, possible caveats must be considered for
the use of primed MSCs, especially for their allogeneic im-
plantation. Previous reports showed these effects on equine
bone marrow-derived MSCs (eBM-MSCs) after inflamma-
tory stimulation, which induced immunoregulation, but also
upregulated MHC expression and impaired viability and
plasticity [10,11]. Therefore, testing lower cytokine dose and
shorter times of exposure for enhancing MSC immunoregu-
latory properties, without compromising immune-evasive
status, viability, and plasticity, could increase MSC thera-
peutic efficacy.
The aim of this study was to assess the effects of cytokine
priming on eBM-MSC immunoregulation, immunogenicity,
viability, and differentiation potential, in search of a balance
between stimulation of their immune-suppressive capac-
ity without related induction of negative effects on other
properties.
Materials and Methods
Animals
Four Shetland pony geldings (aged 4–7 years, weight
138–162 kg) were used as bone marrow (BM) donors. All
horses were determined to be in good health. All procedures
were carried out within the Project License 31/11 approved
by the in-house Ethics Committee for Animal Experiments
from the University of Zaragoza. The care and use of ani-
mals were performed accordingly with the Spanish Policy
for Animal Protection RD53/2013, which meets the Euro-
pean Union Directive 2010/63.
Harvesting and characterization of eBM-MSCS
Twenty microliters of BM from sternumwere obtained using
a 4† 11G Jamshidi needle in heparinized syringes. Equine BM-
MSCs were isolated using a gradient density separation tech-
nique as previously described [12]. Cells were seeded in a
culture medium consisting of low-glucose Dulbecco’s modified
Eagle’s medium (DMEM; Sigma-Aldrich) supplemented with
1% Glutamine (Sigma-Aldrich), 1% Streptomycin/Penicillin
(Sigma-Aldrich), and 10% Fetal Bovine Serum (FBS; Sigma-
Aldrich). Cells were expanded until passage three and charac-
terized by phenotype determination and trilineage differentiation
as previously described [12]. Subsequently, cells were frozen
in 10% DMSO (Sigma-Aldrich)-90% FBS medium and
cryopreserved until experiments started.
Priming of eBM-MSCs
Cryopreserved eBM-MSCs (n= 4) were thawed and seeded
at 5,000 cells/cm2 in the basalmediumat 37Cand5%CO2 for
5 days, allowing readjustments of conditions before initiating
the experiments. A preliminary assay was conducted to select
the optimal timeof exposure to cytokines (SupplementaryData
and Supplementary Fig. S1; Supplementary Data are available
online at www.liebertpub.com/scd) and eBM-MSCs were
exposed for 12 h to 5 ng/mL of TNFa (R&D Systems) plus
5 ng/mL of IFNg (R&D Systems), added to the basal culture
medium described above (CK5-medium). The basal medium
was used as negative control (Control medium). Both control
and CK5 conditions were tested in triplicate. After the 12-h
exposure, eBM-MSCs were detached with 0.25% trypsin-
EDTA (Sigma-Aldrich) and used for subsequent assays. Part
of the cells from both control and CK5 conditions were re-
seeded in the basal medium for additional 7 days to assess if
priming-induced changes in CK5 cells were maintained in
time over control cells by reanalyzing the genes that were
significantly upregulated at 12 h.
Real-time quantitative polymerase chain reaction
Expression of genes related with immunoregulation, im-
munogenicity, apoptosis, and differentiation markers was
analyzed by real-time quantitative polymerase chain reac-
tion (RT-qPCR). Total mRNA from approximately 106
eBM-MSCs from each sample was isolated with the
RNAspin Mini RNA Isolation Kit (GE Healthcare). Geno-
mic DNA was removed with the kit DNAse Turbo (Ambion)
and 1 mg of mRNA from each sample was retrotranscripted
to cDNA by using the Superscript Reverse Trancriptase Kit
(Life Technologies). Isolation of mRNA and cDNA retro-
transcription were performed with the kit Cells-to-cDNA II
(Ambion) in eBM-MSC samples from differentiation assays
and 7-day postpriming assessment. All procedures were
performed according to manufacturer’s instructions.
RT-qPCRs were performed and monitored using a StepOne
Real-Time PCR System device (Applied Biosystems). All re-
actions were carried out using Fast SYBR Green Master Mix
(Applied Biosystems) and 2mL of cDNA as template. Ampli-
ficationwas performed in triplicate following the protocol: 20 s
at 95C, followed by 40 cycles consisting of 3† at 95C and 30†
at 60C. A dissociation curve protocol was run after every
reaction. Levels of gene expression were obtained using the
comparative Ct method. Normalization factor (NF) was cal-
culated as the geometric mean of the quantity of two house-
keeping genes,GAPDH and B2 M [12]. Primers were designed
with the Primer Express 2.0 software based on known equine
sequences. Information about primers is shown in Table 1.
Proliferation
Proliferation after CK5-priming was evaluated by the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bro-
mide (MTT) assay (Sigma-Aldrich) for 6 days as previously
described [13]. Triplicates of each sample were seeded in the
basal medium at 5,000 cells/cm2 in 96-well plates. The basal
medium was used as a blank. Biotek Synergy HT spectro-
photometer was used to measure the optical density (570 nm)
in each well.
Viable cell numbers were determined by extrapolating
from a standard curve consisting of nine triplicated points of
increasing quantity of cells (0–15,000 cells/cm2) as previ-
ously reported [13]. Calibration curve equation for cell
number extrapolation was y = 1 · 10-5 · -0.0349, r2 = 0.997
(y = optical density of the well; x = amount of cells). Cell
doubling times (DT) were calculated according to the for-
mulae: CD= ln [(Nf/Ni)/ln2] and DT=CT/CD, where
DT = cell doubling time; Nf = final number of cells;
Ni = initial number of cells; and CD = cell doubling number.
Assessment of chromatin integrity
Chromatin integrity was evaluated by the chromatin dis-
persion test making use of the D3-Max Kit (Halotech DNA).
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Table 1. Primers Used for Gene Expression by Real-Time Quantitative Polymerase Chain Reaction
Gene Accession number Primer sequence (5¢–3¢) Amplicon size
Housekeeping
GAPDH NM_001163856 F:GGCAAGTTCCATGGCACAGT 128
R:CACAACATATTCAGCACCAGCAT
B2M NM_001082502.2 F: TCGTCCTGCTCGGGCTACT 102
R: ATTCTCTGCTGGGTGACGTGA
Immunomodulation-related molecules
IDO XM_001490681 F: TCATGACTACGTGGACCCAAAA 104
R: CGCCTTCATAGAGCAGACCTTC
iNOS AY027883 F: CCAACAATGGCAACATCAGGT 85
R: TGAGCATTCCAGATCCGGA
IL-6 EU438770 F: AACAGCAAGGAGGTACTGGCA 95
R: CAGGTCTCCTGATTGAACCCA
COX-2 AB041771 F: GTTTGCATTTTTTGCCCAGC 103
R: ACTTAAATCCACCCCGTGACC
IL-10 EU438771 F: GACATCAAGGAGCACGTGAACT 140
R: TGGAGCTTACTGAAGGCACTCT
TGFb-1 AF175709 F: GTCCTTTGATGTCACCGGAGT 137
R: TGGAACTGAACCCGTT
VCAM-1 (CD106) DQ246452 F: TCTATGCTACGCTCTGGCTACG 127
R: TTGATGGTCTCCCCGATGA
CXCR4 XM_001490165 F: TGCAGCAGCAGGTAGCAAAGT 97
R: ATATACGGAACCCGTCCATGG
Antigen-presenting-related molecules
MHC-I AB525081 F: CGTGAGCATCATTGTTGGC 92
R: TCCCTCTTTTTTCACCTGAGG
MHC-II NM_001142816 F: AGCGGCGAGTTGAACCTACAGT 172
R: CGGATCAGACCTGTGGAGATGA
CD40 AY514017 F: ACAAATACTGCGACCCCAACC 114
R: TTTCACAGGCATCGCTGGA
CD80 Krampera 2006 F: CAGGAAAGTTGGCTCTGACCA 135
R: TCTCCATTGTGATCCTGGCTC
CD86 De Schauwer 2014 F: AGTATAAAGGCCGCACAAGC 247
R: CCTTGGGTAGATGAGCAGGT
CD40L XM_001490011 F: AGTTCGAAGGCTTCGTCAAGG 101
R: CGCAATTTGAGGCTCCTGAT
Molecules implied in apoptosis
BAX XM_005596728.1 F: AGTGTCTCAAGCGCATCGG 104
R: CACTCGGAAAAAGACCTCGC
BCL-2 Ryhner, 2008 F: GCCTATCTGGGCCACAAGT 200
R:TTTCCCTTTGGCAGTAAATAGC
Osteogenic markers
ALP XM_001504312 F: GATGGCCTGAACCTCATCGA 92
R: AGTTCGGTCCGGTTCCAGAT
RUNX2 XM_001502519.3 F: CTCCAACCCACGAATGCACTA 80
R: CGGACATACCGAGGGACATG
Adipogenic markers
LPL XM_001489577 F:TGTATGAGAGTTGGGTGCCAAA 70
R:GCCAGTCCACCACAATGACAT
PPARc XM_001492411 F:TGCAAGGGTTTCTTCCGGA 104
R:GCAAGGCATTTCTGAAACCG
Chondrogenic markers
ACAN AF019756 F: CTACGACGCCATCTGCTACA 96
R: ACCGTCTGGATGGTGATGTC
COL2A1 XM_005611082.1 F: TTAGACGCCATGAAGGTTTTCTG 101
R: CTCTTGCTGCTCCACCAGTTCT
GenBank accession numbers of the sequences used for primers design. Primers (F: forward and R: reverse) and length of the amplicon in
base pair (bp). Genes were grouped in agreement with the functions and implications of encoded molecules.
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This methodology was designed to assess DNA damage in
MSCs through minor modification of the previously de-
scribed technique for somatic cumulus cells [14] to MSCs.
DNA damage was visualized using a Proyser fluorescent
microscope (Proyser) employing SyberGreen II fluoro-
chrome (Biotium) at 40· magnification. Cells showing a
large halo of chromatin dispersion were considered to con-
tain highly fragmented DNA (Supplementary Fig. S2). The
percentages of normal cells and eBM-MSCs with frag-
mented DNA were determined in each sample by fluores-
cence microscope count by two independent observers.
Equine BM-MSCs from one control were treated with hy-
drogen peroxide to perform a positive control of DNA
damage through exposition to oxidative stress.
Trilineage differentiation assay
Equine BM-MSCs from both control and CK5 samples
were exposed to the induction medium (differentiation) and
basal medium (negative control) in triplicates according to
each differentiation assay.
Osteogenic differentiation. Equine BM-MSCs were seeded
at 20,000 cells/cm2 density in 24-well plates. The osteogenic
medium consisted of 10 nMdexamethasone (Sigma-Aldrich),
10mM b-glycerophosphate (Sigma-Aldrich), and 100mM
ascorbate-2-phosphate-supplemented (Sigma-Aldrich) basal
medium. After 7 days, differentiation was assessed by Ali-
zarin Red staining. Cells were fixed with 70% ethanol for 1 h
at room temperature (RT), stained with 2%Alizarin Red stain
(pH 4.6) (Sigma-Aldrich) for 10min (RT), and washed with
PBS (Gibco Invitrogen Corporation).
Adipogenic differentiation. Equine BM-MSCs were seeded
at 5,000 cells/cm2 density in 12-well plates. The adipogenic
medium consisted of 1mM dexamethasone (Sigma-Aldrich),
500mM 3-isobutyl-1-methylxanthine (Sigma-Aldrich), 200
mM indomethacin (Sigma-Aldrich), and 15% rabbit serum-
supplemented (Sigma-Aldrich) basal medium. After 15 days,
differentiation was evaluated by Oil Red O staining. The cells
were fixed with 10% formalin (Sigma-Aldrich) for 15min at
RT, stained with 0.3% Oil Red O (Sigma-Aldrich) stain (dis-
solved in 60:40; isopropanol:distilled water) for 30min at
37C, and washed with distilled water.
Chondrogenic differentiation. For chondrogenic differenti-
ation assay, both control and CK5-eBM-MSCs were exposed
to a chondrogenic inductionmedium, but due to the number of
available cells, culture in thebasalmediumwasnot carried out.
Approximately, 300,000 eBM-MSCs from each sample were
transferred to conic bottom 15mL tube and 400mL of chon-
drogenic differentiation mediumwas added and centrifuged at
1,750 rpm for 5min to pellet the cells. The chondrogenic
medium consisted of 10% FBS, 10 ng/mL TGFb-3 (R&D
Systems), ITS+ premix (Beckton Dickinson), 40mg/mL
proline (Sigma-Aldrich), 50mg/mL ascorbate-2-phosphate
(Sigma-Aldrich), and 0.1mM dexamethasone-supplemented
(Sigma-Aldrich) high-glucose DMEM (Sigma-Aldrich).
After 21 days, chondrogenic differentiation was evaluated
by specific staining with Alcian Blue stain. Pellets were fixed
in 10% formalin, embedded in paraffin, and sectioned into 5-
mm sections. The sections were hydrated with increasing
gradients of alcohols, stained with Mayer’s hematoxylin and
3% Alcian Blue dyes, rinsed with distilled water, dehydrated
with decreasing amounts of alcohol, and mounted.
Statistical analysis
Statistical analysis was performed using the SPSS 15.0
(SPSS, Inc.). Normality of each data group was tested with the
Shapiro–Wilk test. Differences in mean cell numbers between
control and CK5 eBM-MSCs along the proliferation assay
were analyzed by the nonparametricANOVAKruskall–Wallis
test with Dunn’s post hoc test. Kruskall–Wallis test was also
used to analyze differences between control-nondifferentiated,
control-differentiated, CK5-nondifferentiated, and CK5-
differentiated eBM-MSCs from trilineage differentiation
assays. Differences in gene expression between CK5-eBM-
MSCsand their controlswere analyzedbyMann–Whitney test.
Differences in percentages of normal (nonfragmented DNA)
and DNA-damaged cells were analyzed between control and
CK5-exposed cells by student’s t test. Significance level was
set at P< 0.05 for all analyses.
Results
Equine BM-MSC immunomodulation
after cytokine priming
Cytokine priming induced significant upregulation of the
immunoregulatory-related genes Vascular Cell Adhesion
Molecule 1 (VCAM-1), Indoleamine 2,3-dioxygenase (IDO),
Inducible Nitric Oxide Synthase (iNOS) (P < 0.01), and In-
terleukin 6 (IL-6) (P< 0.05) by eBM-MSCs. In addition,
nonsignificant upregulation of Cyclooxygenase 2 (COX-2)
and significant downregulation of Interleukin 10 (IL-10)
(P<0.05) were observed (Fig. 1A). Expression of significantly
upregulated genes was evaluated 7 days after CK5-priming and
IL-6, IDO, iNOS, and COX-2 expression remained similar to
unstimulated control and VCAM expression significantly
decreased (P< 0.05) (Fig. 2).
Equine BM-MSC immunogenicity
after cytokine priming
Cytokine priming induced a significant increase in the
expression of MHC-II (P< 0.05) and the costimulatory
molecule CD40 (P< 0.01) by eBM-MSCs. MHC-I was up-
regulated in a nonsignificant manner and the expression
level of costimulatory molecules CD80, CD86, and CD40L
remained unchanged (Fig. 1B). Seven days after the 12-h
cytokine priming, the expression level of most relevant
immunogenic molecules was assessed and MHC-I and
MHC-II expression decreased, reaching similar values than
in control cells (Fig. 2).
Equine BM-MSC viability after cytokine priming
Proliferation assay. Proliferation data are presented in
Fig. 3A. CK-exposed cells grew in a similar manner to control
cells: significant differences in the number of cells were not
observed between control and CK5-exposed cells and cell DT
was similar between control cells (3.071 – 1.316 days) and
CK5-stimulated eBM-MSCs (3.280 – 1.307 days).
Apoptosis gene expression. Proapoptotic gene BCL2-
Associated X Protein (BAX) was downregulated in CK5-
eBM-MSCs compared to control cells (P < 0.005), whereas
there were no significant differences between control and
stimulated cells for the antiapoptotic gene BCL-2 (Fig. 3B).
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Chromatin integrity. Percentage of normal cells (non-
fragmented chromatin) and DNA-damaged cells (dis-
persed chromatin fragments) did not show significant
differences between control and CK5-eBM-MSC samples
(Fig. 3C).
Equine BM-MSC differentiation
after cytokine priming
Osteogenic, adipogenic, and chondrogenic differentiation
were achieved in control cells from all animals. Sponta-
neous differentiation was not observed in any of the non-
differentiated controls (Fig. 4A, B).
Osteogenic differentiation. Osteogenic differentiation was
confirmed in both control and CK5-exposed eBM-MSCs by
positive staining of the calcium deposits with Alizarin Red
(Fig. 4C, D). Alkaline phosphatase (ALP) and Runt-related
transcription factor 2 (RUNX2) gene expression was signifi-
cantly higher (P< 0.05) in both control andCK5-differentiated
samples over their corresponding nondifferentiated cells. In
FIG. 2. Immunomodulatory and immunogenic related
molecule expression 7 days after CK5-priming. Gene ex-
pression data are reported as mean (n = 4) fold increase or
decrease of CK5-stimulated eBM-MSC gene expression
over unstimulated control eBM-MSCs. (*=P < 0.05).
FIG. 1. Gene expression data are reported as mean (n= 4)
fold increase or decrease of CK5-stimulated eBM-MSC gene
expression over unstimulated control eBM-MSC. (A) Im-
munomodulatory related molecule expression after 12 h of
CK5 priming; (B) immunogenic related molecule expression
after 12 h of CK5-priming. (* =P< 0.05; **=P < 0.01). eBM-
MSCs, equine bonemarrow-derivedmesenchymal stem cells.
FIG. 3. Data from viability assays. (A) Proliferation data
are presented as mean (n = 4) –SEM cell count of CK5-
stimulated and CK5-unstimulated control eBM-MSCs at
each time point. (B) Gene expression of apoptosis-related
genes BAX and BCL-2 in control and CK5-exposed eBM-
MSCs. Data are reported as mean (n= 4) fold increase or
decrease of CK5-stimulated eBM-MSC gene expression
over unstimulated control eBM-MSCs. (C) Chromatin in-
tegrity assessment data are presented as percentage of nor-
mal (nonfragmented DNA) and DNA-damaged eBM-MSCs
for both control and CK5-stimulated samples.
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addition, expression of RUNX2 was significantly higher
(P< 0.05) in differentiated control eBM-MSCs over differ-
entiated CK5-exposed cells (Fig. 5A1–2)
Adipogenic differentiation. Lipid droplets were detected in
both control and CK5-exposed eBM-MSCs under adipo-
genic induction by Oil red O staining (Fig. 4E, F). Lipo-
protein lipase (LPL) mRNA level was significantly higher
only in differentiated CK5-eBM-MSCs over correspondent
nondifferentiated cells (P< 0.05) (Fig. 5B1).
Chondrogenic differentiation. Chondrogenic phenotype
was achieved by both control and CK5-exposed cells, de-
tected by positive blue staining of the extracellular matrix
by Alcian Blue staining and lacunae formation (Fig. 4G, H).
Both aggrecan (ACAN) and collagen type II alpha I
(COL2A1) showed similar level of mRNA relative expres-
sion in both differentiated control and CK5-eBM-MSCs
(Fig. 5C).
Discussion
TNFa and IFNg synergistically induce eBM-MSC im-
munoregulatory abilities [10], but certain cytokine con-
centrations and time of exposure also produce a decrease
in their proliferation and differentiation abilities [11].
Therefore, eBM-MSC stimulation with a lower cytokine
dose and a shorter time of exposure was tested to reach
immunoregulatory induction without impairing viability
and plasticity or increasing immunogenicity. Concentration
of cytokines was chosen from a previous report in other
species [3] and the time of exposure was set according to a
preliminary assay.
Both cell–cell contact and paracrine signaling mechanisms
are implied in the immunoregulatory functions of MSCs [2].
The adhesion molecule VCAM-1 participates in immuno-
suppression exerted by MSCs [15] and it was upregulated by
CK5 priming, supporting the participation of direct cell-
contact pathways in the eBM-MSC immunoregulatory
mechanisms. Adhesion molecules are also related to MSC
recruitment and migration, and these processes are particu-
larly complex in inflammatory environments, showing both
enhancement [16] and impairment of this ability [17]. The
chemokine receptor CXCR4 participates inMSCmigration in
other species [18], but this is not evident in equine MSCs
according to our findings and previous reports [10].
Paracrine signaling immunomodulation mechanism is
mainly governed by molecules such as IDO, iNOS, IL-6,
and COX-2, eliciting different mechanisms on immune cells
[2], and TNFa and IFNg are reported as inductors of these
molecules by MSCs from different species and sources
[19,20]. CK5-priming of eBM-MSCs led to a significant
increase in the expression of immunomodulatory-related
genes, similar to previous reports in equine species using
higher cytokine concentrations [10]. IL-10 and TGF-b1
could also participate in MSC immune mechanisms [2,21],
but other reports have shown that inflammatory exposure
could elicit different effects on these molecules, ranging
from increases in their production [22], no change of their
expression/secretion [23], or even a significant reduction
[24]. CK5-priming did not alter TGF-b1, but downregulated
IL-10 expression, similar to previous findings in eBM-MSCs
stimulated with higher cytokine doses [10].
Since immunoregulatory mechanisms can vary between
different species and MSC sources [20], a variety of factors
could participate in the MSC immunosuppression mecha-
nisms. Our findings suggest that IL-10 and TGF-b1 may not
have a major role in eBM-MSC immunoregulation, whereas
IDO, iNOS, IL-6, or COX-2 would be mainly involved.
Changes induced in eBM-MSC immunoregulatory-related
gene expression by CK5-priming confirmed that a lower
dose and a shorter time of exposure to proinflammatory
cytokines can induce a similar enhancement in the eBM-
MSC immunomodulatory profile to that described using
higher cytokine concentrations and longer exposure [10].
Inflammatory environments could also produce a rise in
MSC immunogenicity, with adverse safety and efficacy
FIG. 4. Staining for osteogenic, adipogenic, and chon-
drogenic differentiation of control and CK5-stimulated
eBM-MSCs. Control (A) and CK5-stimulated (B) undiffer-
entiated cells (magnification 4 · ); Alizarin Red staining of
eBM-MSCs differentiated into osteoblasts, control (C), and
CK5 exposed (D); Oil Red O staining of eBM-MSCs dif-
ferentiated into adipocytes, control (E), and CK5 exposed
(F) (magnification 10 · ); Alcian Blue staining of pellets
from eBM-MSCs undergoing chondrogenic differentiation,
control (G), and CK5 exposed (H) (magnification 20 · ).
20 BARRACHINA ET AL.
implications for their allogeneic use. Allogeneic MSC
therapy is especially interesting when cell therapy is needed
immediately or there are handicaps for autologous MSC use,
such as aged and/or diseased patients [25,26].
Therefore, preservation of low immunogenicity after in-
flammatory stimulation is important to allow safe MSC al-
logeneic transplantation. Inflammatory stimuli, particularly
IFNg, might induce MHC expression [5,27]. CK5-priming
induced a significant increase of MHC-II expression in eBM-
MSCs, as it was observed with higher doses and longer ex-
posure [10]. Even so, IFNg-induced MHC upregulation may
not lead to an increase in immunogenicity because of the lack
of costimulatory molecules CD40, CD40L, CD80, and CD86
MSC expression, needed for antigenic recognition [28,29].
Nevertheless, inflammatory conditions might upregulate
CD40 expression in human MSCs without affecting the ex-
pression of CD80, CD86, and CD40L [27,30]. In a similar
manner, CD40 significant upregulation was detected after
CK5-priming. However, absence of changes on costimulatory
molecules CD80, CD86, and CD40L expression, combined
with the upregulation of immunoregulatory molecules, sug-
gests that eBM-MSCs might conserve their immune-evasive
status after inflammatory priming [31].
Immunoregulatory functions of MSCs might be improved
by proinflammatory cytokine priming, but how long these
changes are maintained for after the stimulation remains
unknown. Our results showed that the overexpression of
VCAM-I, IL-6, iNOS, and COX-2 achieved by CK5-priming
was not maintained after 7 days. In the same way, MHC-II
upregulation did not remain after 7 days. These facts suggest
that changes induced by cytokine priming might be short-
term events, which may not remain for long after the in vivo
implantation.
Furthermore, TNFa and IFNg may synergistically induce
apoptosis in murine MSCs [8]. However, there are con-
flicting reports showing that these cytokines can also
FIG. 5. Gene expression
results of trilineage differen-
tiation assay. Results from
osteogenesis (A.1–2) and adi-
pogenesis (B.1–2) are ex-
pressed asmean–SEM (n= 4)
fold increase or decrease of
differentiated control eBM-
MSCs (CTRL.DIF), non-
differentiated CK5-exposed
eBM-MSCs (CK5.NON-DIF),
and differentiated CK5-
exposed eBM-MSCs (CK5.
DIF) over control non-
differentiated cells (CTRL.
NON-DIF). Results from
chondrogenic assay (C) are
presented as mean–SEM
(n=4) mRNA relative expres-
sion of CTRL.DIF and
CK5.DIF eBM-MSCs. (*=P<
0.05; N.E=no expression).
INFLAMMATORY PRIMING INFLUENCE ON EBM-MSC IMMUNE PROFILE 21
promote human and murine MSC proliferation [24,32].
CK5-priming did not alter the regular growth of eBM-MSCs
and relevant changes in the expression of genes involved in
apoptosis [33] or chromatin integrity [34] were not induced.
These findings suggest that CK5-priming is well tolerated
and does not hamper eBM-MSC viability.
Impairment ofMSCdifferentiation ability by inflammatory
environment has been well documented [6]. TNFa inhibits
RUNX2 expression in human and rat [7,35] and IFNg might
prevent MSC osteogenesis in vivo in allogeneic implants in
mice [36]. High level of TNFa leads to a reduction in PPARc
expression by rat MSCs undergoing adipogenesis [37] and
might also impair the chondrogenesis of murine and ratMSCs
[6]. Possible mechanisms participating in the differentiation
inhibition by inflammatory environment have been described
in humanMSCs [38], but on the other hand, TNFamight have
osteogenic promotive effects. Indeed, TNFa enhanced human
MSC osteogenic differentiation as measured by increases in
the ALP activity and matrix mineralization [7], increasing
Osteocalcin [39], RUNX2, Osterix, and bone morphogenetic
protein 2 (BMP-2) expression [32].
In eBM-MSCs, adverse effects of TNFa and IFNg expo-
sure on trilineage differentiation have been reported when
using higher cytokine doses and exposure time [11]. Never-
theless, eBM-MSCs were able to differentiate into the three
lineages after CK5-priming. Previous studies describing dif-
ferentiation impairment generally used cytokine concentra-
tions similar to those used in this study, but these were added
to the culture medium along the differentiation induction
[6,7,35], whereas we pretreated cells and induced differenti-
ation without adding these cytokines. Other studies using
cytokine pretreatment and subsequent regular differentiation
induction also reported negative effects, but these studies used
higher amounts of cytokines for priming MSCs [11,40].
In summary, the effect of proinflammatory cytokines onMSC
differentiation is considered detrimental, but under certain con-
ditions, they can promote an enhancing effect. Our results sug-
gest that a short cytokine exposure with low doses is well
tolerated by eBM-MSCs,without abolishing their differentiation
mechanisms or allowing its recovery after CK5-priming.
In conclusion, priming eBM-MSCs with 5 ng/mL of TNFa
and IFNg for 12h showed an upregulation of immunoregulatory-
related genes without a significant increase of most of the
immunogenic ones and without eBM-MSC viability and
plasticity impairment. Since the inflammatory environment
in a naturally occurring disease, like in equine joint injury,
could be heterogeneous and may not consistently induce
changes in the immunoregulatory MSC profile [10], eBM-
MSC CK5-priming enables this induction.
The stimulation with TNFa and IFNg of MSC popula-
tions with initially different immunosuppressive capacity
increases regulatory ability to a similar level, leading to
homogenous MSC immunosuppressive capacity between
different cell populations [41]. Consequently, prior ex vivo
priming of eBM-MSCs could improve the effectiveness of
cellular therapy. In addition, immunogenicity, viability, and
plasticity of eBM-MSCs after cytokine priming must be
considered. Viability and differentiation abilities of eBM-
MSCs were preserved after CK5-priming. Furthermore, the
possible effect of upregulated MHC-II might be attenuated by
the lack of costimulatory molecules and by the enhancement
in the immunomodulatory expression profile by eBM-MSCs.
This work contributes to clarify the effects of inflammatory
exposure on eBM-MSCs and constitutes a previous step to
enhance their therapeutic use. Further studies will be needed
to clarify the effect of cytokine priming on the safety and
efficacy of eBM-MSCs.
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